JP2014515753A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515753A5 JP2014515753A5 JP2014505641A JP2014505641A JP2014515753A5 JP 2014515753 A5 JP2014515753 A5 JP 2014515753A5 JP 2014505641 A JP2014505641 A JP 2014505641A JP 2014505641 A JP2014505641 A JP 2014505641A JP 2014515753 A5 JP2014515753 A5 JP 2014515753A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- binding site
- group
- formula
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CN(*)C(N(C)*)=O Chemical compound CN(*)C(N(C)*)=O 0.000 description 3
Applications Claiming Priority (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11163474 | 2011-04-21 | ||
| EP11163470.5 | 2011-04-21 | ||
| EP11163472.1 | 2011-04-21 | ||
| EP11163474.7 | 2011-04-21 | ||
| EP11163467.1 | 2011-04-21 | ||
| EP11163472 | 2011-04-21 | ||
| EP11163467 | 2011-04-21 | ||
| EP11163470 | 2011-04-21 | ||
| EP11168557 | 2011-06-01 | ||
| EP11168556.6 | 2011-06-01 | ||
| EP11168558 | 2011-06-01 | ||
| EP11168558.2 | 2011-06-01 | ||
| EP11168559 | 2011-06-01 | ||
| EP11168559.0 | 2011-06-01 | ||
| EP11168556 | 2011-06-01 | ||
| EP11168557.4 | 2011-06-01 | ||
| EP11193621 | 2011-12-14 | ||
| EP11193618 | 2011-12-14 | ||
| EP11193609.2 | 2011-12-14 | ||
| EP11193609 | 2011-12-14 | ||
| EP11193618.3 | 2011-12-14 | ||
| EP11193623 | 2011-12-14 | ||
| EP11193621.7 | 2011-12-14 | ||
| EP11193623.3 | 2011-12-14 | ||
| PCT/EP2012/057243 WO2012143495A2 (de) | 2011-04-21 | 2012-04-20 | Neue binder-wirkstoff konjugate (adcs) und ihre verwendung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014515753A JP2014515753A (ja) | 2014-07-03 |
| JP2014515753A5 true JP2014515753A5 (OSRAM) | 2015-09-24 |
Family
ID=45976407
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014505641A Withdrawn JP2014515753A (ja) | 2011-04-21 | 2012-04-20 | 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用 |
| JP2014505642A Expired - Fee Related JP6088488B2 (ja) | 2011-04-21 | 2012-04-20 | 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用 |
| JP2016109316A Expired - Fee Related JP6250735B2 (ja) | 2011-04-21 | 2016-05-31 | 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014505642A Expired - Fee Related JP6088488B2 (ja) | 2011-04-21 | 2012-04-20 | 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用 |
| JP2016109316A Expired - Fee Related JP6250735B2 (ja) | 2011-04-21 | 2016-05-31 | 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (7) | US20130122024A1 (OSRAM) |
| EP (2) | EP3501546A3 (OSRAM) |
| JP (3) | JP2014515753A (OSRAM) |
| KR (2) | KR20140122649A (OSRAM) |
| CN (3) | CN106117312A (OSRAM) |
| AR (2) | AR086363A1 (OSRAM) |
| AU (3) | AU2012244673A1 (OSRAM) |
| BR (1) | BR112013027119A8 (OSRAM) |
| CA (3) | CA3027793A1 (OSRAM) |
| IL (2) | IL228841A (OSRAM) |
| MX (1) | MX2013012253A (OSRAM) |
| RU (2) | RU2013151599A (OSRAM) |
| SG (2) | SG194567A1 (OSRAM) |
| TW (2) | TWI582112B (OSRAM) |
| WO (4) | WO2012143496A2 (OSRAM) |
| ZA (1) | ZA201307955B (OSRAM) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32560A (es) | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| RS56161B1 (sr) * | 2009-12-09 | 2017-11-30 | Bayer Pharma AG | Antitela protiv c4.4a i njihove primene |
| CA2801971C (en) * | 2010-06-10 | 2018-07-24 | Hans-Georg Lerchen | Novel auristatin derivatives and their use |
| ES2553874T3 (es) | 2010-09-29 | 2015-12-14 | Seattle Genetics, Inc. | N-Carboxialquil-auristatinas y su uso |
| CA2829736C (en) | 2011-03-16 | 2020-07-21 | Seattle Genetics, Inc. | N-carboxyalkylauristatins and use thereof |
| EP3501546A3 (de) | 2011-04-21 | 2019-09-18 | Seattle Genetics, Inc. | Cystein-wirkstoff konjugate und ihre verwendung |
| MX2014007121A (es) * | 2011-12-14 | 2014-09-04 | Seattle Genetics Inc | Nuevos conjugados de principio activo-ligante (adc) y su uso. |
| WO2014093379A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
| JP6262768B2 (ja) * | 2013-01-03 | 2018-01-17 | セルトリオン， インク． | 抗体−リンカー−薬物結合体、その製造方法およびそれを含む抗癌剤組成物 |
| US9522876B2 (en) | 2013-03-15 | 2016-12-20 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| FR3005051A1 (fr) * | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
| BR112015030514A2 (pt) * | 2013-06-04 | 2017-08-29 | Cytomx Therapeutics Inc | Composições e métodos para conjugação de anticorpos ativáveis |
| DK3060256T3 (da) * | 2013-10-25 | 2019-07-29 | Bayer Pharma AG | Hidtil ukendt stabil formulering |
| CA2928952A1 (en) * | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
| JP6636925B2 (ja) | 2013-12-17 | 2020-01-29 | ノバルティス アーゲー | 細胞障害性ペプチドおよびその抱合体 |
| CA2934617A1 (en) | 2013-12-23 | 2015-07-02 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with kinesin spindle protein (ksp) |
| ES2916722T3 (es) | 2013-12-27 | 2022-07-05 | Zymeworks Inc | Sistemas de enlace que contienen sulfonamida para conjugados de fármacos |
| SG11201605260VA (en) | 2013-12-27 | 2016-07-28 | Zymeworks Inc | Var2csa-drug conjugates |
| FI3122757T3 (fi) | 2014-02-28 | 2023-10-10 | Hangzhou Dac Biotech Co Ltd | Varautuneita linkkereitä ja niiden konjugointikäyttötapoja |
| US9260478B2 (en) | 2014-04-04 | 2016-02-16 | Shanghui Hu | Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis |
| WO2015183978A1 (en) * | 2014-05-28 | 2015-12-03 | Agensys, Inc. | Derivatives of dolaproine-dolaisoleuine peptides |
| EA201692530A1 (ru) | 2014-06-13 | 2017-07-31 | Новартис Аг | Цитотоксические пептиды и их конъюгаты |
| EP3194421B1 (en) | 2014-09-17 | 2021-11-03 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| CN105820248A (zh) * | 2015-01-07 | 2016-08-03 | 上海张江生物技术有限公司 | 一种新型抗egfr单克隆抗体的制备方法及应用 |
| AU2016218840A1 (en) * | 2015-02-15 | 2017-08-31 | Jiangsu Hengrui Medicine Co., Ltd. | Ligand-cytotoxicity drug conjugate, preparing method therefor, and application thereof |
| HUE056376T2 (hu) * | 2015-03-19 | 2022-02-28 | Hangzhou Dac Biotech Co Ltd | Új hidrofil kapcsolók és azok ligandum-gyógyszer konjugátumai |
| EP3283522A1 (en) | 2015-04-17 | 2018-02-21 | Spring Bioscience Corporation | Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a |
| US10526287B2 (en) | 2015-04-23 | 2020-01-07 | Constellation Pharmaceuticals, Inc. | LSD1 inhibitors and uses thereof |
| WO2015151079A2 (en) * | 2015-06-20 | 2015-10-08 | Hangzhou Dac Biotech Co, Ltd | Auristatin analogues and their conjugates with cell-binding molecules |
| AU2016282723B2 (en) | 2015-06-22 | 2021-09-23 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups |
| WO2017019489A1 (en) * | 2015-07-24 | 2017-02-02 | George Robert Pettit | Quinstatin compounds |
| US10722593B2 (en) | 2015-10-02 | 2020-07-28 | Sirenas Llc | Anti-cancer compounds and conjugates thereof |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| JP2019510000A (ja) * | 2016-02-26 | 2019-04-11 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | 新規トキシン及びその中間体の製造方法 |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| JP7251981B2 (ja) | 2016-03-24 | 2023-04-04 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
| WO2017216028A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| WO2018006785A1 (zh) * | 2016-07-05 | 2018-01-11 | 江苏恒瑞医药股份有限公司 | Egfr抗体-药物偶联物及其在医药上的应用 |
| US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
| MD3532459T2 (ro) | 2016-10-26 | 2024-06-30 | Constellation Pharmaceuticals Inc | Inhibitori ai LSD1 și utilizările medicale ale acestora |
| JP7350313B2 (ja) | 2016-12-16 | 2023-09-26 | ブルーフィン バイオメディシン， インコーポレイテッド | 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 |
| CA3047491A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| KR102556826B1 (ko) | 2016-12-21 | 2023-07-18 | 바이엘 파마 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc) |
| WO2018114804A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| KR102760578B1 (ko) | 2016-12-22 | 2025-02-03 | 큐 바이오파마, 인크. | T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법 |
| KR20210125094A (ko) * | 2017-04-06 | 2021-10-15 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 비스-링키지를 사용한 세포독성 약물의 접합 |
| BR112020000581A2 (pt) * | 2017-07-12 | 2020-07-14 | Nouscom Ag | polipeptídeo, ácido nucleico, vetor, coleção de um ou mais vetores de expressão, composição compreendendo uma vacina e kit de vacinação |
| US10646585B2 (en) | 2017-09-15 | 2020-05-12 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and ligand-drug conjugates thereof |
| CN107998453B (zh) * | 2017-12-12 | 2020-09-25 | 中山大学附属第一医院 | 一种表面改性的脱细胞基质及其改性方法 |
| GB201721265D0 (en) * | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| WO2019149637A1 (en) | 2018-01-31 | 2019-08-08 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| MX2020009842A (es) | 2018-03-23 | 2020-10-15 | Seattle Genetics Inc | Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido. |
| WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| AR120430A1 (es) | 2019-11-08 | 2022-02-16 | Humanigen Inc | Células car-t dirigidas a epha3 para el tratamiento de tumores |
| PH12022551426A1 (en) * | 2020-01-06 | 2023-11-20 | Cytomx Therapeutics Inc | Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| EP4247433A1 (en) * | 2020-11-19 | 2023-09-27 | Ardeagen Corporation | Gpc3 binding agents, conjugates thereof and methods of using the same |
| EP4247853A4 (en) | 2020-11-20 | 2025-02-12 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. | MODIFIED EGFR ANTIBODY WITH REDUCED AFFINITY, DRUG CONJUGATE AND USE THEREOF |
| WO2022216848A1 (en) * | 2021-04-06 | 2022-10-13 | Hemoshear Therapeutics, Inc. | Methods of treating methylmalonic acidemia and propionic acidemia |
| EP4400121A1 (en) | 2021-09-03 | 2024-07-17 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| CN115957338B (zh) * | 2021-10-12 | 2025-11-18 | 成都科岭源医药技术有限公司 | 一种高稳定性的靶向接头-药物偶联物 |
| CA3238167A1 (en) | 2021-11-19 | 2023-05-25 | Maria Leia Smith | Gpc3 binding agents, conjugates thereof and methods of using the same |
| CN114149343B (zh) * | 2021-12-06 | 2023-10-20 | 中节能万润股份有限公司 | 一种高纯度1,4-二氰基-2-丁烯的制备方法 |
| WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
| CA3258612A1 (en) * | 2022-06-09 | 2023-12-14 | Beigene, Ltd. | Antibody drug conjugates |
| JP2025524986A (ja) * | 2022-07-27 | 2025-08-01 | メディボストン リミテッド | オーリスタチン誘導体およびそのコンジュゲート |
| EP4653017A1 (en) | 2023-01-18 | 2025-11-26 | Tyligand Bioscience (Shanghai) Limited | Antibody-drug conjugate and use thereof |
| CN116239513B (zh) * | 2023-05-05 | 2023-08-18 | 天津凯莱英制药有限公司 | Mmae关键中间体的制备方法、mmae的制备方法和抗体偶联药物 |
| US20260048137A1 (en) | 2024-08-16 | 2026-02-19 | Ardeagen Corporation | Anti-mesothelin antibody conjugates and methods of use thereof |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1981003688A1 (en) | 1980-06-13 | 1981-12-24 | Crosby Valve & Eng Co Ltd | Fluid pressure relief system actuator |
| FR2499737B1 (fr) | 1981-02-12 | 1985-07-05 | Laudren Cie Sa Ets M | Circuit d'alarme pour systemes de surveillance de postes telephoniques publics a prepaiement |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| DE3265843D1 (en) | 1981-07-30 | 1985-10-03 | Shell Int Research | Process for the preparation of carbonate esters |
| DE3223868A1 (de) | 1982-06-25 | 1983-12-29 | Friedrich 8541 Röttenbach Schweinfurter | Turbinenpumpe |
| GR81257B (OSRAM) | 1982-12-04 | 1984-12-11 | Lilly Industries Ltd | |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB2163883B (en) | 1984-08-29 | 1989-02-01 | British Aerospace | Data processing arrangement |
| FR2576708B1 (fr) | 1985-01-25 | 1987-04-30 | Novatome | Generateur de vapeur dont le fluide caloporteur est du metal liquide et dont la detection des fuites est effectuee par prelevement de ce metal liquide |
| US4606662A (en) | 1985-01-31 | 1986-08-19 | International Business Machines Corporation | Single stepping motor ribbon and correction feed and lift system |
| US4640839A (en) | 1985-07-01 | 1987-02-03 | Nestec S.A. | Agglomeration process |
| DE8808645U1 (de) | 1988-07-06 | 1988-08-25 | Hofer, Daniel, 7730 Villingen-Schwenningen | Anzeigeeinrichtung für Feuerlöscher |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| DE69032979T2 (de) | 1989-10-20 | 1999-11-04 | Medarex, Inc. | Bispezifische heteroantikörper mit zweifachen effektorfunktionen |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| JP3583420B2 (ja) | 1990-10-05 | 2004-11-04 | メダレツクス・インコーポレーテツド | 二特異的試薬を用いた標的免疫化 |
| AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| SK281143B6 (sk) | 1991-03-06 | 2000-12-11 | Merck Patent Gesellschaft Mit Beschr�Nkter Haftung | Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok |
| IE921342A1 (en) | 1991-04-26 | 1992-11-04 | Surface Active Ltd | Novel antibodies, and methods for their use |
| WO1993017715A1 (en) | 1992-03-05 | 1993-09-16 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
| DE69531187T2 (de) | 1994-12-20 | 2004-04-22 | Merck Patent Gmbh | Monoklonaler Antikörper gegen das Alpha-V-Integrin |
| ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| ATE318147T1 (de) | 1996-03-25 | 2006-03-15 | Medarex Inc | Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen |
| US6150508A (en) | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| WO2000003737A2 (en) * | 1998-07-17 | 2000-01-27 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Water-soluble drugs and methods for their production |
| MXPA01011502A (es) | 1999-05-14 | 2003-08-20 | Boehringer Ingelheim Pharma | Compuestos de tipo profarmaco anti-tumorigenos, activados por enzimas. |
| EP2042194A3 (en) | 1999-05-14 | 2009-04-22 | Imclone Systems, Inc. | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| NZ517331A (en) | 1999-07-29 | 2004-02-27 | Medarex Inc | Human monoclonal antibodies to prostate specific membrane antigen and a transgenic mouse to produce the antibody |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| WO2001023553A2 (en) | 1999-09-29 | 2001-04-05 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Metastasis-associated antigen c4.4a |
| PL357448A1 (en) | 2000-02-25 | 2004-07-26 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services | Anti-egfrviii scfvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof |
| ES2259030T3 (es) | 2000-05-19 | 2006-09-16 | Scancell Limited | Anticuerpos humanizados frente al receptor del factor de crecimiento epidermico. |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| AUPR395801A0 (en) | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
| AU2002334799B2 (en) | 2001-04-26 | 2009-05-07 | Biogen Ma Inc. | Cripto-specific antibodies |
| ES2321065T3 (es) | 2001-04-26 | 2009-06-02 | Biogen Idec Ma Inc. | Anticuerpos bloqueantes de cripto y usos de los mismos. |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US7589180B2 (en) | 2001-05-11 | 2009-09-15 | Abbott Laboratories Inc. | Specific binding proteins and uses thereof |
| WO2002100348A2 (en) | 2001-06-13 | 2002-12-19 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| CN1646160A (zh) | 2002-03-13 | 2005-07-27 | 拜奥根Idec马萨诸塞公司 | 抗αvβ6抗体 |
| CN101824090B (zh) | 2002-06-14 | 2013-01-02 | 免疫医疗公司 | 人源化单克隆抗体hPAM4 |
| ES2544527T3 (es) | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
| WO2004091375A2 (en) | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Epha2 and non-neoplastic hyperproliferative cell disorders |
| US7736644B2 (en) | 2003-06-27 | 2010-06-15 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| KR101672664B1 (ko) | 2003-07-21 | 2016-11-04 | 이뮤노젠 아이엔씨 | 인간화된 항체 또는 그의 항원결정기 결합절편 |
| EP3434275A1 (en) * | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Assay for cancer cells based on the use of auristatin conjugates with antibodies |
| EP1701979A2 (en) | 2003-12-03 | 2006-09-20 | Xencor, Inc. | Optimized antibodies that target the epidermal growth factor receptor |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| WO2005090407A1 (en) | 2004-03-19 | 2005-09-29 | Imclone Systems Incorporated | Human anti-epidermal growth factor receptor antibody |
| WO2005101017A1 (en) * | 2004-04-07 | 2005-10-27 | Genentech, Inc. | Mass spectrometry of antibody conjugates |
| JP2008515889A (ja) * | 2004-10-05 | 2008-05-15 | ジェネンテック・インコーポレーテッド | 毒性の低下した治療剤 |
| JP2008519863A (ja) | 2004-11-12 | 2008-06-12 | シアトル ジェネティクス インコーポレイティッド | Ｎ末端にアミノ安息香酸単位を有するオーリスタチン |
| WO2006071441A2 (en) * | 2004-11-30 | 2006-07-06 | Curagen Corporation | Antibodies directed to gpnmb and uses thereof |
| PL1819359T3 (pl) | 2004-12-09 | 2015-08-31 | Janssen Biotech Inc | Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie |
| ES2343746T3 (es) | 2005-01-07 | 2010-08-09 | Diadexus, Inc. | Composiciones de anticuerpo ovr110 y metodos de uso. |
| EP1848745B1 (en) | 2005-02-18 | 2014-07-09 | Medarex, L.L.C. | Monoclonal antibodies against cd30 lacking in fucosyl residues |
| JP5171621B2 (ja) | 2005-07-07 | 2013-03-27 | シアトル ジェネティックス， インコーポレイテッド | フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物 |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| EP3539572A1 (en) | 2005-08-24 | 2019-09-18 | ImmunoGen, Inc. | Process for preparing maytansinoid antibody conjugates |
| AU2006287416A1 (en) * | 2005-09-07 | 2007-03-15 | Medimmune, Llc | Toxin conjugated Eph receptor antibodies |
| NZ566395A (en) | 2005-09-26 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to CD70 |
| AU2006315580A1 (en) * | 2005-11-10 | 2007-05-24 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen |
| DOP2006000277A (es) | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
| WO2007140371A2 (en) * | 2006-05-30 | 2007-12-06 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| WO2008004834A1 (en) | 2006-07-06 | 2008-01-10 | Isu Abxis Co., Ltd | Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor |
| JP5401314B2 (ja) | 2006-09-08 | 2014-01-29 | メディミューン，エルエルシー | ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用 |
| PT2073842E (pt) | 2006-09-10 | 2015-04-07 | Glycotope Gmbh | Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos |
| CA2660795C (en) | 2006-09-18 | 2014-11-18 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
| WO2008133641A2 (en) * | 2006-10-11 | 2008-11-06 | Curagen Corporation | Antibodies directed to gpnmb and uses thereof |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| DK2099823T4 (da) | 2006-12-01 | 2022-05-09 | Seagen Inc | Målbindingsmiddelvarianter og anvendelser deraf |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| US9283276B2 (en) | 2007-08-14 | 2016-03-15 | Ludwig Institute For Cancer Research Ltd. | Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| PT2185574E (pt) | 2007-09-07 | 2013-08-26 | Agensys Inc | Anticorpos e moléculas relacionadas que se ligam a proteínas 24p4c12 |
| US8039597B2 (en) | 2007-09-07 | 2011-10-18 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
| SI2195017T1 (sl) * | 2007-10-01 | 2015-01-30 | Bristol-Myers Squibb Company | Človeška protitelesa, ki vežejo mezotelin in njihova uporaba |
| HUE027358T2 (en) | 2007-11-26 | 2016-09-28 | Bayer Ip Gmbh | Anti-mesothelin antibodies and their applications |
| HRP20140604T1 (hr) | 2007-12-26 | 2014-09-12 | Biotest Ag | Sredstva koja djeluju na cd138 i njihova upotreba |
| JP5817034B2 (ja) | 2007-12-26 | 2015-11-18 | バイオテスト・アクチエンゲゼルシヤフト | Ｃｄ１３８を標的とする免疫複合体及びその使用 |
| PT2247620T (pt) * | 2008-01-31 | 2016-08-23 | Genentech Inc | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização |
| WO2009105871A1 (en) | 2008-02-25 | 2009-09-03 | Prittie Family Trust 89 | Raised image plate construction with regions of varying support thickness beneath the image areas |
| JP2011517555A (ja) * | 2008-03-14 | 2011-06-16 | ジェネンテック， インコーポレイテッド | 薬剤耐性に関連する遺伝的変異 |
| EP2265283B1 (en) * | 2008-03-18 | 2014-09-03 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
| HUE029925T2 (en) | 2008-04-02 | 2017-04-28 | Macrogenics Inc | HER2 / neu-specific antibodies and methods using them |
| EP2277044B1 (en) * | 2008-05-13 | 2015-06-17 | Genentech, Inc. | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
| EP2331577B1 (en) | 2008-08-29 | 2017-06-07 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
| US20100247484A1 (en) | 2009-03-31 | 2010-09-30 | Heinrich Barchet | Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3 |
| SG174963A1 (en) | 2009-03-31 | 2011-11-28 | Roche Glycart Ag | Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan |
| BRPI1015179A2 (pt) | 2009-06-19 | 2016-04-19 | Merck Patent Gmbh | biomarcadores e métodos para a determinação de eficácia de anticorpos anti-egfr em terapia de câncer |
| AU2010303415B2 (en) | 2009-10-07 | 2015-02-19 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
| RS56161B1 (sr) | 2009-12-09 | 2017-11-30 | Bayer Pharma AG | Antitela protiv c4.4a i njihove primene |
| CA2801971C (en) * | 2010-06-10 | 2018-07-24 | Hans-Georg Lerchen | Novel auristatin derivatives and their use |
| ES2553874T3 (es) * | 2010-09-29 | 2015-12-14 | Seattle Genetics, Inc. | N-Carboxialquil-auristatinas y su uso |
| PE20170917A1 (es) * | 2010-12-20 | 2017-07-12 | Genentech Inc | Anticuerpos anti-mesotelina e inmunoconjugados |
| US9302799B2 (en) * | 2011-02-17 | 2016-04-05 | Sabic Global Technologies B.V. | Method for bulk transporting 2,6-xylenol susceptible to oxidative discoloration |
| CA2829736C (en) | 2011-03-16 | 2020-07-21 | Seattle Genetics, Inc. | N-carboxyalkylauristatins and use thereof |
| EP3501546A3 (de) | 2011-04-21 | 2019-09-18 | Seattle Genetics, Inc. | Cystein-wirkstoff konjugate und ihre verwendung |
| MX2014007121A (es) | 2011-12-14 | 2014-09-04 | Seattle Genetics Inc | Nuevos conjugados de principio activo-ligante (adc) y su uso. |
-
2012
- 2012-04-20 EP EP19150066.9A patent/EP3501546A3/de not_active Withdrawn
- 2012-04-20 CA CA3027793A patent/CA3027793A1/en not_active Abandoned
- 2012-04-20 CA CA2833477A patent/CA2833477A1/en not_active Abandoned
- 2012-04-20 SG SG2013078282A patent/SG194567A1/en unknown
- 2012-04-20 CA CA2833690A patent/CA2833690A1/en not_active Abandoned
- 2012-04-20 AR ARP120101371A patent/AR086363A1/es unknown
- 2012-04-20 US US13/451,916 patent/US20130122024A1/en not_active Abandoned
- 2012-04-20 WO PCT/EP2012/057245 patent/WO2012143496A2/de not_active Ceased
- 2012-04-20 KR KR1020137030468A patent/KR20140122649A/ko not_active Withdrawn
- 2012-04-20 US US14/113,070 patent/US20140127240A1/en not_active Abandoned
- 2012-04-20 AU AU2012244673A patent/AU2012244673A1/en not_active Abandoned
- 2012-04-20 WO PCT/EP2012/057249 patent/WO2012143499A2/de not_active Ceased
- 2012-04-20 MX MX2013012253A patent/MX2013012253A/es active IP Right Grant
- 2012-04-20 JP JP2014505641A patent/JP2014515753A/ja not_active Withdrawn
- 2012-04-20 BR BR112013027119A patent/BR112013027119A8/pt not_active IP Right Cessation
- 2012-04-20 WO PCT/EP2012/057243 patent/WO2012143495A2/de not_active Ceased
- 2012-04-20 AR ARP120101372A patent/AR086364A1/es unknown
- 2012-04-20 WO PCT/EP2012/057247 patent/WO2012143497A2/de not_active Ceased
- 2012-04-20 CN CN201610450907.7A patent/CN106117312A/zh active Pending
- 2012-04-20 CN CN201280028243.5A patent/CN103764170A/zh active Pending
- 2012-04-20 TW TW101114203A patent/TWI582112B/zh not_active IP Right Cessation
- 2012-04-20 CN CN201280019602.0A patent/CN103826661B/zh not_active Expired - Fee Related
- 2012-04-20 US US13/451,950 patent/US20130066055A1/en not_active Abandoned
- 2012-04-20 TW TW106103491A patent/TWI636793B/zh not_active IP Right Cessation
- 2012-04-20 JP JP2014505642A patent/JP6088488B2/ja not_active Expired - Fee Related
- 2012-04-20 RU RU2013151599/04A patent/RU2013151599A/ru not_active Application Discontinuation
- 2012-04-20 SG SG10201702384PA patent/SG10201702384PA/en unknown
- 2012-04-20 RU RU2013151600A patent/RU2610336C2/ru not_active IP Right Cessation
- 2012-04-20 EP EP12718624.5A patent/EP2699268A2/de not_active Withdrawn
- 2012-04-20 KR KR1020137030493A patent/KR102023496B1/ko not_active Expired - Fee Related
- 2012-04-20 AU AU2012244675A patent/AU2012244675B2/en not_active Ceased
- 2012-10-20 US US13/656,681 patent/US8992932B2/en not_active Expired - Fee Related
-
2013
- 2013-10-13 IL IL228841A patent/IL228841A/en active IP Right Grant
- 2013-10-24 ZA ZA2013/07955A patent/ZA201307955B/en unknown
-
2014
- 2014-05-05 US US14/269,577 patent/US20150030618A1/en not_active Abandoned
-
2015
- 2015-05-11 US US14/708,914 patent/US20150246136A1/en not_active Abandoned
-
2016
- 2016-02-24 US US15/052,655 patent/US20160193359A1/en not_active Abandoned
- 2016-05-31 JP JP2016109316A patent/JP6250735B2/ja not_active Expired - Fee Related
- 2016-09-26 IL IL248036A patent/IL248036B/en active IP Right Grant
-
2017
- 2017-06-09 AU AU2017203928A patent/AU2017203928B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013151599A (ru) | Новые конъюгаты связывающее соединение-активное соединение (adc) и их применение | |
| JP2014512375A5 (OSRAM) | ||
| AU2021201765B2 (en) | Hydrophilic Linkers for Conjugate | |
| ES2815098T3 (es) | Conjugados de ligadores (ADCs) con inhibidores de KSP | |
| MX2014007121A (es) | Nuevos conjugados de principio activo-ligante (adc) y su uso. | |
| ES2781523T3 (es) | Conjugados de moléculas de unión celular con agentes citotóxicos | |
| EP3600444A1 (en) | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | |
| JP2017512752A (ja) | 親水性抗体−薬物コンジュゲート | |
| RU2016148680A (ru) | Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение | |
| NZ625745B2 (en) | FGFR antibody drug conjugates (ADCs) and the use thereof | |
| TW201339175A (zh) | 新黏合劑－藥物接合體（ａｄｃ）及其用途 |